Advanced Method for the Identification of Patients with Inherited Hypercholesterolemia

Familial hypercholesterolemia (FH) has a prevalence of 1 in 500 in Western society and predisposes for premature cardiovascular disease. Lipid-lowering treatment of affected individuals is widely advocated. Maximum health benefit can be obtained in FH if treatment is started as early as possible, as the World Health Organization has recently recommended. In 1994 we initiated an active case-finding program for individuals with FH, based on family investigation and DNA-testing. In an initial pilot study we established that active family screening supported by DNA diagnostics resulted in the identification of substantial numbers of FH heterozygotes and determined that diagnosis by DNA analysis was superior to conventional cholesterol measurement. Since its initiation, the program has led to the identification of more than 6000 individuals with FH, of whom the greatest part was not adequately treated at the time of identification. Our findings indicate not only that this case-finding approach is effective in identifying FH patients who otherwise would not have been identified but also that the vast majority of these patients seek treatment and are successfully started on cholesterol-lowering therapy to reduce their risk of premature cardiovascular disease. Here we describe an effective model to identify and bring under treatment large numbers of individuals affected by FH.

KEYWORDS

Familial hypercholesterolemia - cardiovascular disease - prevention - case-finding - genetic testing

REFERENCES

• 1 Familial Hypercholesterolaemia: report of a WHO consultation. World Health Organization, Human Genetics Programme, Division of Noncommunicable Diseases. WHO/HGN/FH/CONS/98.7. Paris, October 1997
• 2 Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet. 1994;  344 1383-1389
• 3 Shepherd J, Cobbe S, Ford I et al.. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (WOSCOPS).  N Engl J Med. 1995;  333 1301-1307
• 4 Sacks F M, Pfeffer M A, Moye L A et al.. The effect of pravastatin on coronary events in patients with average cholesterol levels (CARE).  N Engl J Med. 1996;  335 1001-1009
• 5 Downs J R, Clearfield M, Weis S et al.. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels (AFCAPS/TexCAPS).  JAMA. 1998;  279 1615-1622
• 6 The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group . Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.  N Eng J Med. 1998;  339 1349-1357
• 7 Vogt T M. Risk assessment and health hazard appraisal.  Annu Rev Public Health. 1981;  2 31-47
• 8 Goldstein J L, Hobbs H H, Brown M S. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D The Metabolic Basis of Inherited Disease. New York; McGraw-Hill 2001: 2863-2913
• 9 Hill J S, Hayden M R, Frohlich J et al.. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia.  Arterioscler Thromb. 1991;  11 290-297
• 10 Scientific Steering Committee on behalf of the Simon Broome Register Group . Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management.  Atherosclerosis. 1999;  142 105-115
• 11 Defesche J C. Familial hypercholesterolaemia. In: Betteridge DJ Lipids and Vascular Disease. London; Martin Dunitz Ltd 2000: 65-76
• 12 Smilde T H, Van Wissen S, Wollersheim H, Trip M D, Kastelein J JP, Stalenhoef A FH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial.  Lancet. 2001;  357 577-581
• 13 Lansberg P J, Tuzgöl S, Van de Ree M A, Defesche J C, Kastelein J J. The prevalence of familial hypercholesterolemia among adults in general practice is higher than expected [in Dutch].  Ned Tijdschr Geneeskd. 2000;  144 1437-1440
• 14 Fouchier S W, Defesche J C, Umans-Eckenhausen M AW, Kastelein J JP. The molecular basis of familial hypercholesterolemia in the Netherlands.  Hum Genet. 2001;  109 602-615
• 15 Umans-Eckenhausen M AW, Defesche J C, Sijbrands E JG, Scheerder R LJM, Kastelein J JP. Review of the first 5 years of screening for familial hypercholesteroleamia in the Netherlands.  Lancet. 2001;  357 165-168
• 16 Nijbroek G, Sood S, McIntosh I et al.. Fifteen novel FBN1 mutations causing Marfan syndrome detected by heteroduplex analysis of genome amplicons.  Am J Hum Genet. 1995;  57 8-21
• 17 Bridges A B, Fead M, Boxer M, Gray J R, Bundy C, Murray A. Marfan syndrome in a large family: response of family members to a screening program.  J Med Genet. 1992;  29 81-85
• 18 Wonderling D, Umans-Eckenhausen M AW, Marks D, Defesche J C, Kastelein J JP, Thorogood M. A cost-effectiveness analysis of the genetic screening programme for familial hypercholesterolemia in The Netherlands.  Semin Vasc Med. 2004;  4 97-104
• 19 Tonstad S, Nøvik T C, Vandvik I H. Psychosocial function during treatment for familial hypercholesterolemia.  Pediatrics. 1996;  98 249-255
• 20 Umans-Eckenhausen M A, Oort F J, Ferenschild K C, Defesche J C, Kastelein J J, de Haes J C. Parental attitude towards genetic testing for familial hypercholesterolemia in children.  J Med Genet. 2002;  39 e49
• 21 De Jongh S, Kerckhoffs M C, Grootenhuis M A et al.. The influence of statin therapy on quality of life, anxiety and concerns in children with familial hypercholesterolemia and their parents.  Acta Paediatr. 2003;  92 1096-1101